Evidence map›Paper›PMID 36819811›Full record

ArticleEcancermedicalscience2022

Endometrial carcinosarcoma: a poor prognosis debut with favourable therapeutic outcome.

María Fernanda Toro-Wills, Angelina Álvarez-Londoño, Abraham Hernández-Blanquisett, Fernando Salas Marquez, María Cristina Martínez-Ávila

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Ecancermedicalscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Cells · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

María Fernanda Toro-WillsDepartment of Gynecology, Centro Hospitalario Serena del Mar, Cartagena 130001, Colombia.
Angelina Álvarez-LondoñoDepartment of Radiation Oncology, Cancer Institute, Centro Hospitalario Serena del Mar, Cartagena 130001, Colombia.
Abraham Hernández-BlanquisettDepartment of Clinical Oncology, Cancer Institute, Centro Hospitalario Serena del Mar, Cartagena 130001, Colombia.
Fernando Salas MarquezDepartment of Gynecology Oncology, Centro Hospitalario Serena del Mar, Cartagena 130001, Colombia.
María Cristina Martínez-ÁvilaDepartment of Clinical Oncology, Cancer Institute, Centro Hospitalario Serena del Mar, Cartagena 130001, Colombia.
Hospital Provincial de Rosario · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial carcinosarcoma (ECS) is a rare, highly aggressive disease characterised by a biphasic growth of malignant epithelial (carcinomatous) and mesenchymal (sarcomatous) components. Clinically, it cannot be distinguished from endometrial carcinoma or uterine sarcoma. The definitive diagnosis can only be made based on histological examination and immunohistochemistry. To date, there aren't standardised treatment protocols for its management. We report a case of a 73-year-old patient who presented postmenopausal abnormal uterine bleeding and was diagnosed with ECS. A non-conventional treatment approach was conducted with favourable oncological outcomes.

Indexed as

carcinosarcomachemotherapyendometrial canceroverall survivalradiotherapytherapeutic approach

Identifiers

PMID36819811
PMCPMC9934871
OpenAlexW4309607630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.